Vanguard Group’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$29.8M Sell
3,265,802
-1,811,486
-36% -$16.5M ﹤0.01% 2368
2025
Q1
$40.4M Buy
5,077,288
+239,119
+5% +$1.9M ﹤0.01% 2178
2024
Q4
$26.3M Sell
4,838,169
-922,280
-16% -$5.01M ﹤0.01% 2455
2024
Q3
$41.6M Sell
5,760,449
-655,872
-10% -$4.74M ﹤0.01% 2258
2024
Q2
$69.7M Buy
6,416,321
+664,948
+12% +$7.22M ﹤0.01% 2013
2024
Q1
$108M Buy
5,751,373
+432,013
+8% +$8.1M ﹤0.01% 1818
2023
Q4
$115M Buy
5,319,360
+111,358
+2% +$2.41M ﹤0.01% 1790
2023
Q3
$107M Buy
5,208,002
+175,565
+3% +$3.61M ﹤0.01% 1773
2023
Q2
$237M Buy
5,032,437
+52,666
+1% +$2.48M 0.01% 1382
2023
Q1
$209M Buy
4,979,771
+94,219
+2% +$3.95M 0.01% 1429
2022
Q4
$186M Buy
4,885,552
+97,687
+2% +$3.73M 0.01% 1471
2022
Q3
$187M Buy
4,787,865
+45,026
+0.9% +$1.76M 0.01% 1421
2022
Q2
$153M Buy
4,742,839
+117,836
+3% +$3.81M ﹤0.01% 1581
2022
Q1
$153M Buy
4,625,003
+46,762
+1% +$1.55M ﹤0.01% 1718
2021
Q4
$195M Sell
4,578,241
-253,028
-5% -$10.8M ﹤0.01% 1627
2021
Q3
$214M Buy
4,831,269
+6,459
+0.1% +$286K 0.01% 1563
2021
Q2
$274M Buy
4,824,810
+66,772
+1% +$3.79M 0.01% 1425
2021
Q1
$356M Buy
4,758,038
+158,923
+3% +$11.9M 0.01% 1187
2020
Q4
$398M Buy
4,599,115
+78,675
+2% +$6.81M 0.01% 1011
2020
Q3
$276M Sell
4,520,440
-212,592
-4% -$13M 0.01% 1058
2020
Q2
$197M Sell
4,733,032
-101,820
-2% -$4.23M 0.01% 1279
2020
Q1
$139M Buy
4,834,852
+144,070
+3% +$4.14M 0.01% 1337
2019
Q4
$339M Buy
4,690,782
+44,521
+1% +$3.21M 0.01% 1055
2019
Q3
$652M Buy
4,646,261
+39,831
+0.9% +$5.59M 0.02% 673
2019
Q2
$843M Buy
4,606,430
+40,731
+0.9% +$7.46M 0.03% 575
2019
Q1
$726M Buy
4,565,699
+543,229
+14% +$86.4M 0.03% 607
2018
Q4
$385M Sell
4,022,470
-63,342
-2% -$6.07M 0.02% 835
2018
Q3
$577M Buy
4,085,812
+262,990
+7% +$37.1M 0.02% 718
2018
Q2
$598M Buy
3,822,822
+60,038
+2% +$9.4M 0.03% 682
2018
Q1
$606M Buy
3,762,784
+410,339
+12% +$66.1M 0.03% 654
2017
Q4
$552M Buy
3,352,445
+522,193
+18% +$86M 0.02% 708
2017
Q3
$176M Buy
2,830,252
+80,298
+3% +$5M 0.01% 1360
2017
Q2
$219M Buy
2,749,954
+58,679
+2% +$4.67M 0.01% 1171
2017
Q1
$191M Buy
2,691,275
+261,759
+11% +$18.6M 0.01% 1246
2016
Q4
$124M Buy
2,429,516
+132,749
+6% +$6.78M 0.01% 1493
2016
Q3
$106M Buy
2,296,767
+554,206
+32% +$25.5M 0.01% 1523
2016
Q2
$52.5M Buy
1,742,561
+121,186
+7% +$3.65M ﹤0.01% 1880
2016
Q1
$52M Buy
1,621,375
+289,398
+22% +$9.28M ﹤0.01% 1847
2015
Q4
$77.7M Buy
1,331,977
+199,316
+18% +$11.6M 0.01% 1641
2015
Q3
$47.9M Buy
1,132,661
+272,472
+32% +$11.5M ﹤0.01% 1892
2015
Q2
$62.8M Buy
860,189
+237,246
+38% +$17.3M ﹤0.01% 1816
2015
Q1
$31.3M Buy
622,943
+400,198
+180% +$20.1M ﹤0.01% 2139
2014
Q4
$8.15M Buy
222,745
+190,220
+585% +$6.96M ﹤0.01% 2638
2014
Q3
$1.02M Buy
+32,525
New +$1.02M ﹤0.01% 3499